| Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. The company has a strategic alliance with Nationwide Children's Hospital for the advancement of microdystrophin gene therapy program under the research and option agreement, as well as Galgt2 gene therapy program under the license agreement; Catabasis Pharmaceuticals, Inc to explore a combination drug treatment approach for DMD under the research collaboration agreement; and Charley's Fund, Inc. to support the development of product candidates using its proprietary exon-skipping technologies under the research agreement. It also has a license agreement with the University of Western Australia for treatment of DMD by inducing the skipping of certain exons; collaboration and license agreement with Summit (Oxford) Ltd. for the development of ezutromid, an utrophin modulator which is in phase II clinical trials for the treatment of DMD; and a gene therapy research collaboration with Genethon to develop treatments for Duchenne muscular dystrophy. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| INGRAM DOUGLAS S | President & CEO | Jul 27 | Buy | 42.50 | 47,058 | 1,999,965 | 382,058 | Jul 28 08:51 AM | | Howton David T | SVP, General Counsel | Jul 21 | Option Exercise | 20.56 | 1,000 | 20,565 | 23,301 | Jul 21 09:46 PM | | Mahatme Sandesh | EVP, CFO & CBO | Jul 21 | Option Exercise | 23.85 | 1,500 | 35,775 | 33,861 | Jul 21 09:49 PM | | Ruff Shamim | SVP, Regulatory Affairs & Qual | Jul 21 | Option Exercise | 14.12 | 5,888 | 83,133 | 25,450 | Jul 21 09:47 PM | | Ruff Shamim | SVP, Regulatory Affairs & Qual | Jul 21 | Sale | 44.00 | 4,388 | 193,072 | 21,062 | Jul 21 09:47 PM | | Ruff Shamim | SVP, Regulatory Affairs & Qual | Jul 20 | Option Exercise | 13.71 | 6,250 | 85,688 | 27,312 | Jul 21 09:47 PM | | Mahatme Sandesh | EVP, CFO & CBO | Jul 20 | Option Exercise | 15.38 | 50,000 | 769,107 | 65,359 | Jul 21 09:49 PM | | Cumbo Alexander | SVP, Chief Commercial Officer | Jul 20 | Option Exercise | 13.71 | 2,500 | 34,275 | 22,793 | Jul 21 09:45 PM | | Howton David T | SVP, General Counsel | Jul 20 | Option Exercise | 13.71 | 25,000 | 342,750 | 41,357 | Jul 21 09:46 PM | | Howton David T | SVP, General Counsel | Jul 20 | Sale | 41.00 | 25,000 | 1,025,000 | 22,301 | Jul 21 09:46 PM | | Cumbo Alexander | SVP, Chief Commercial Officer | Jul 20 | Sale | 41.00 | 5,918 | 242,638 | 16,875 | Jul 21 09:45 PM | | Mahatme Sandesh | EVP, CFO & CBO | Jul 20 | Sale | 41.00 | 50,000 | 2,050,000 | 32,361 | Jul 21 09:49 PM | | Kaye Edward M. MD | Director | Jul 20 | Sale | 41.00 | 10,000 | 410,000 | 52,471 | Jul 21 09:48 PM | | Ruff Shamim | SVP, Regulatory Affairs & Qual | Jul 20 | Sale | 42.00 | 6,250 | 262,500 | 21,062 | Jul 21 09:47 PM | | Howton David T | SVP, General Counsel | Nov 09 | Option Exercise | 23.85 | 1,000 | 23,850 | 22,453 | Nov 10 08:27 AM | | Mahatme Sandesh | Senior Vice President, CFO | Nov 09 | Option Exercise | 23.85 | 1,000 | 23,850 | 32,532 | Nov 10 08:26 AM | | Kaye Edward M. MD | President, CEO & CMO | Nov 09 | Option Exercise | 8.28 | 3,000 | 24,840 | 75,635 | Nov 10 08:19 AM | | Ruff Shamim | SVP, Regulatory Affairs & Qual | Nov 08 | Option Exercise | 26.24 | 1,000 | 26,240 | 21,239 | Nov 10 08:20 AM | | Mahatme Sandesh | Senior Vice President, CFO | Oct 17 | Option Exercise | 13.90 | 30,000 | 417,000 | 61,532 | Oct 19 04:22 PM | | Mahatme Sandesh | Senior Vice President, CFO | Oct 17 | Sale | 50.08 | 30,000 | 1,502,502 | 31,532 | Oct 19 04:22 PM | | Howton David T | SVP, General Counsel | Sep 22 | Option Exercise | 13.90 | 7,000 | 97,300 | 28,453 | Sep 26 04:19 PM | | Kaye Edward M. MD | President, CEO & CMO | Sep 22 | Option Exercise | 8.28 | 40,179 | 332,682 | 117,162 | Sep 26 04:23 PM | | Ruff Shamim | SVP, Regulatory Affairs & Qual | Sep 22 | Option Exercise | 13.90 | 7,311 | 101,623 | 27,550 | Sep 30 09:58 PM | | Ruff Shamim | SVP, Regulatory Affairs & Qual | Sep 22 | Sale | 60.00 | 7,311 | 438,660 | 20,239 | Sep 30 09:58 PM | | Kaye Edward M. MD | President, CEO & CMO | Sep 22 | Sale | 60.00 | 40,179 | 2,410,740 | 76,983 | Sep 26 04:23 PM | | Howton David T | SVP, General Counsel | Sep 22 | Sale | 60.00 | 7,000 | 420,000 | 21,453 | Sep 26 04:19 PM |
|
